Borderline ovarian tumors and low-grade serous carcinoma: A retrospective analysis from argentine and Uruguayan oncology centers.

INTRODUCTION

Borderline ovarian tumors (BOT) and low-grade serous carcinoma (LGSC) are rare epithelial ovarian neoplasms with distinct clinicopathologic features and generally more favorable outcomes than high-grade epithelial tumors. This study aimed to describe the clinical, pathologic, and treatment characteristics of BOT and LGSC treated in Argentine and Uruguayan oncology centers, and to report oncologic outcomes.

MATERIALS AND

METHODS

A multicenter retrospective study was conducted including 369 adult patients diagnosed between 2009 and 2020 in 19 hospitals in Argentina and 1 in Uruguay. Clinical, pathologic, surgical, treatment, and survival data were collected from medical records.

RESULTS

Of the 369 patients, 336 (91.1%) had BOT and 33 (8.9%) had LGSC. Most tumors were diagnosed at an early stage. BOT was more frequently associated with stage I disease, conservative surgery, and very limited use of systemic treatment, whereas LGSC showed more bilateral disease, ascites, neovascularization, invasive pathologic features, greater use of staging-related procedures, and more frequent systemic treatment. In BOT, 5-year overall survival (OS) and recurrence-free survival (RFS) were 98.9% and 90.2%, respectively. In LGSC, the corresponding rates were 91.4% and 75.5%.

CONCLUSIONS

BOT and LGSC showed clearly different clinical, pathologic, treatment, and survival profiles in this South American multicenter cohort. BOT was usually diagnosed at an early stage and had excellent oncologic outcomes, whereas LGSC was associated with more aggressive clinicopathologic features, more frequent systemic treatment, and poorer survival.